Recent Advanced Research in Hypertension

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 2323

Editor


E-Mail Website
Guest Editor
1. Instituto de Fisiología, Facultad de Medicina—INSIBIO, Universidad Nacional de Tucumán, CONICET, San Miguel de Tucumán 4000, Argentina
2. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA
Interests: cardiovascular; metabolic and renal disease related to hypertension; hypertension

Special Issue Information

Dear Colleagues,

Hypertension remains a leading cause of cardiovascular disease and mortality worldwide, affecting over 1.5 billion people globally. The complexity of its etiology involves genetic, environmental, and lifestyle factors, making it a multifaceted health issue. Recent advancements in research have facilitated a deeper understanding of the pathophysiological mechanisms underlying hypertension, leading to innovative therapeutic approaches and improved management strategies. Among the critical components under investigation is the area of sex differences in hypertension. It has become increasingly evident that there are significant biological and sociocultural differences between men and women that influence the prevalence, pathophysiology, and treatment responses associated with hypertension. This special issue aims to compile cutting-edge research that reflects recent advances in hypertension, providing a multidisciplinary approach that integrates findings from clinical, translational, and basic research.

The proposed special issue will focus on a variety of recent advances in the field of hypertension, encouraging submissions that highlight both basic and clinical research, including but not limited to the following areas:

  1. Pathophysiology: New insights into the biological mechanisms driving hypertension, including the role of the renin-angiotensin-aldosterone system (RAAS), insulin resistance with associated hyperinsulinemia, endothelial dysfunction, and neurohormonal influences with consideration of how these mechanisms differ between sexes.
  2. Sex Differences in Hypertension: Exploration of how sex influences the incidence, progression, and severity of hypertension, including hormonal effects, variations in vascular function, and differences in cardiovascular remodeling.
  3. Novel Therapeutic Targets: Examination of how emerging pharmacological agents may yield different efficacy and side effects based on the patient’s sex and hormonal status.
  4. Precision Medicine in Hypertension: Studies focusing on personalized treatment strategies informed by sex-specific genetic and phenotypic characteristics of patients.
  5. Technological Innovations*: The role of digital health technologies and wearable devices in monitoring and managing hypertension, with a focus on sex-differences in user engagement and outcomes.

Dr. Rodrigo Maranon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hypertension
  • sex differences
  • pathophysiology
  • precision medicine
  • novel therapeutics
  • digital health
  • cardiovascular disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 1339 KB  
Review
Blood Pressure Variability (BPV) as a Novel Digital Biomarker of Multisystem Risk and Diagnostic Insight: Measurement, Mechanisms, and Emerging Artificial Intelligence Methods
by Lakshmi Sree Pugalenthi, Sidhartha Gautam Senapati, Jay Gohri, Hema Latha Anam, Hritik Madan, Adi Arora, Avni Arora, Jieun Lee, Gayathri Yerrapragada, Poonguzhali Elangovan, Mohammed Naveed Shariff, Thangeswaran Natarajan, Jayarajasekaran Janarthanan, Shreshta Agarwal, Shiva Sankari Karuppiah, Divyanshi Sood, Swetha Rapolu, Vivek N. Iyer, Scott A. Helgeson and Shivaram P. Arunachalam
Biomedicines 2026, 14(2), 317; https://doi.org/10.3390/biomedicines14020317 - 30 Jan 2026
Cited by 1 | Viewed by 1985
Abstract
Hypertension has been traditionally known to be highlighted by mean blood pressure; however, emerging evidence exhibits that blood pressure variability (BPV), including short-term, day-to-day, and visit-to-visit fluctuations can have an implication across multiple body systems. Elevated BPV reflects repetitive hemodynamic stress, affecting the [...] Read more.
Hypertension has been traditionally known to be highlighted by mean blood pressure; however, emerging evidence exhibits that blood pressure variability (BPV), including short-term, day-to-day, and visit-to-visit fluctuations can have an implication across multiple body systems. Elevated BPV reflects repetitive hemodynamic stress, affecting the physiologic hemostasis contributing to vascular injury and end organ damage. This narrative review is a compilation of recent evidence on the prognostic value of BPV, explained by pathophysiology, various devices with its measurement approaches, and, essentially, the clinical implication of BPV and the use of such devices utilizing artificial intelligence. A comprehensive literature search across PubMed, Cochrane Library, Scopus, and Web of Science were conducted, focusing on observational studies, cohorts, randomized trials, and meta-analyses. Higher BPV has been associated with an increased risk of cardiovascular mortality, stroke, coronary events, and heart failure, the progression of chronic kidney disease, cognitive decline, and preeclampsia, among other end organ damage, despite mean blood pressure. The various pathophysiologic mechanisms include autonomic dysregulation, arterial stiffness, endothelial dysfunction, circadian rhythm alteration, and systemic inflammation, which result in vascular remodeling and multisystem damage. Antihypertensive medications such as calcium channel blockers and renin–angiotensin–aldosterone system inhibitors seem to reduce BPV; randomized trials have not specifically investigated their BPV-reducing effects. The aim of this review is to highlight that BPV is a dynamic marker of multisystem risk, and question how various AI-based devices can aid continuous BPV monitoring and patient specific risk stratification. Full article
(This article belongs to the Special Issue Recent Advanced Research in Hypertension)
Show Figures

Graphical abstract

Back to TopTop